Monash University review finds high-potency THC medicinal cannabis prescribed without clinical evaluation

A review of Australian medicinal cannabis prescriptions reveals that products with THC concentrations up to four times higher than those tested in clinical trials are being widely distributed. The study highlights a regulatory gap where the vast majority of available products have not undergone formal evaluation by the Therapeutic Goods Administration, raising concerns regarding patient safety and clinical efficacy.